Evercore ISI began coverage on shares of Hologic (NASDAQ:HOLX) in a report released on Wednesday, January 3rd, Marketbeat reports. The brokerage issued an outperform rating and a $50.00 price objective on the medical equipment provider’s stock.

Other research analysts have also recently issued research reports about the company. Cowen upgraded Hologic from a market perform rating to an outperform rating and set a $51.00 price objective on the stock in a research note on Monday, December 11th. Piper Jaffray Companies restated a buy rating and set a $48.00 price objective on shares of Hologic in a research note on Thursday, November 9th. Zacks Investment Research upgraded Hologic from a sell rating to a hold rating in a research note on Tuesday, October 31st. Royal Bank of Canada reiterated a hold rating and issued a $42.00 price target on shares of Hologic in a research note on Friday, September 22nd. Finally, Jefferies Group reiterated a buy rating and issued a $44.00 price target (down previously from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $48.79.

Shares of Hologic (NASDAQ:HOLX) opened at $43.75 on Wednesday. Hologic has a 1 year low of $35.76 and a 1 year high of $46.80. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. The company has a market capitalization of $12,060.00, a price-to-earnings ratio of 16.57, a PEG ratio of 2.03 and a beta of 0.95.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. During the same quarter in the previous year, the business earned $0.52 earnings per share. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. analysts expect that Hologic will post 2.18 EPS for the current year.

In related news, Director Elaine Ullian sold 9,282 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. Insiders sold a total of 12,099 shares of company stock valued at $487,223 over the last three months. Corporate insiders own 0.79% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Hologic by 0.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock worth $944,000 after purchasing an additional 85 shares during the period. Symphony Asset Management LLC lifted its position in shares of Hologic by 0.4% during the 2nd quarter. Symphony Asset Management LLC now owns 28,005 shares of the medical equipment provider’s stock valued at $1,271,000 after acquiring an additional 108 shares during the last quarter. Hall Laurie J Trustee lifted its position in shares of Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Hologic by 3.4% during the 2nd quarter. Pacer Advisors Inc. now owns 8,413 shares of the medical equipment provider’s stock valued at $382,000 after acquiring an additional 279 shares during the last quarter. Finally, Sentry Investment Management LLC lifted its position in shares of Hologic by 1.9% during the 2nd quarter. Sentry Investment Management LLC now owns 18,491 shares of the medical equipment provider’s stock valued at $839,000 after acquiring an additional 353 shares during the last quarter. Hedge funds and other institutional investors own 97.10% of the company’s stock.

WARNING: “Hologic (HOLX) Earns Outperform Rating from Analysts at Evercore ISI” was originally published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.mareainformativa.com/2018/01/30/hologic-holx-receives-new-coverage-from-analysts-at-evercore-isi-updated-updated-updated.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.